Table 4:
Medical therapy for therapeutic and prophylactic mastectomies.
| Characteristic | Therapeutic Mastectomies | Prophylactic Mastectomies | ||||||
|---|---|---|---|---|---|---|---|---|
| Autologous Fat Grafting | Autologous Fat Grafting | |||||||
| Overall | No AFG | AFG | p | Overall | No AFG | AFG | p | |
| Number of Mastectomies | 273 | 200 | 73 | 155 | 112 | 43 | ||
| Chemotherapy, n (%) | 0.036† | 0.578 | ||||||
| Adjuvant | 124 (45.4) | 89 (44.5) | 35 (47.9) | 58 (37.4) | 43 (38.4) | 15 (34.9) | ||
| Neoadjuvant | 20 (7.3) | 15 (7.5) | 5 (6.8) | 17 (11.0) | 14 (12.5) | 3 (7.0) | ||
| None | 118 (43.2) | 92 (4546.0) | 26 (35.6) | 73 (47.1) | 51 (45.5) | 22 (51.2) | ||
| Unknown | 11 (4.0) | 4 (2.0) | 7 (9.6) | 7 (4.5) | 4 (3.6) | 3 (7.0) | ||
| Hormone Therapy, n (%) | 167 (61.2) | 127 (63.5) | 40 (54.8) | 0.244 | 79 (51.0) | 62 (55.4 | 17 (39.5) | 0.113 |
| Tamoxifen | 117 (42.9) | 88 (44.0) | 29 (39.7) | 0.622 | 59 (38.1) | 47 (42.0) | 12 (27.9) | 0.153 |
| Anastrozole | 43 (15.8) | 36 (18.0) | 7 (9.6) | 0.133 | 13 (8.4) | 11 (9.8) | 2 (4.7) | 0.518 |
| Letrozole | 20 (7.3) | 13 (6.5) | 7 (9.6) | 0.545 | 12 (7.7) | 8 (7.1 | 4 (9.3) | 0.739 |
| Exemestane | 15 (5.5) | 10 (5.0) | 5 (6.8) | 0.555 | 6 (3.9) | 5 (4.5) | 1 (2.3) | 1.000 |
| Raloxifene | 1 (0.4) | 1 (0.5) | 0 (0.0) | 1.000 | ||||
| Lupron | 2 (0.7) | 2 (1.0) | 0 (0.0) | 1.000 | ||||
| Immunotherapy, n (%) | 30 (11.0) | 22 (11.0) | 8 (11.0) | 1.000 | 14 (9.0) | 11 (9.8) | 3 (7.0) | 0.759 |
| Radiation, n (%) | 48 (17.6) | 28 (14.0) | 20 (27.4) | 0.017† | 24 (15.5) | 16 (14.3) | 8 (18.6) | 0.676 |